Lithium valproate - BioLink Life Sciences

Drug Profile

Lithium valproate - BioLink Life Sciences

Alternative Names: LiVal

Latest Information Update: 04 Aug 2016

Price : $50

At a glance

  • Originator BioLink Life Sciences
  • Class
  • Mechanism of Action 4-aminobutyrate transaminase inhibitors; Glutamate decarboxylase stimulants; Neurotransmitter modulators; Sodium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Manic episodes; Seizures

Highest Development Phases

  • Preclinical Manic episodes; Seizures

Most Recent Events

  • 03 Aug 2016 Preclinical trials in Seizures in USA (PO)
  • 03 Aug 2016 Lithium valproate - BioLink Life Sciences is available for licensing as of 04 Aug 2016. http://www.biolinkonline.com/
  • 31 Dec 2015 Preclinical trials in Manic episodes in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top